最新巻号

巻号一覧
臨床薬理
- Vol.48(2017)
- Vol.47(2016)
- Vol.46(2015)
- Vol.45(2014)
- Vol.44(2013)
- Vol.43(2012)
- Vol.42(2011)
- Vol.41(2010)
- Vol.40(2009)
- Vol.39(2008)
- Vol.38(2007)
- Vol.37(2006)
- Vol.36(2005)
- Vol.35(2004)
- Vol.34(2003)
- Vol.33(2002)
- Vol.32(2001)
- Vol.31(2000)
- Vol.30(1999)
- Vol.29(1998)
- Vol.28(1997)
- Vol.27(1996)
- Vol.26(1995)
- Vol.25(1994)
- Vol.24(1993)
- Vol.23(1992)
- Vol.22(1991)
- Vol.21(1990)
- Vol.20(1989)
- Vol.19(1988)
- Vol.18(1987)
- Vol.17(1986)
- Vol.16(1985)
- Vol.15(1984)
- Vol.14(1983)
- Vol.13(1982)
- Vol.12(1981)
- Vol.11(1980)
- Vol.10(1979)
- Vol.9(1978)
- Vol.8(1977)
- Vol.7(1976)
- Vol.6(1975)
- Vol.5(1974)
- Vol.4(1973)
- Vol.3(1972)
- Vol.2(1971)
- Vol.1(1970)

臨床薬理 Vol. 48(2017) No. 4

原著

Optimizing a Single Monthly Dose of Risedronate Based on its Weekly Dose in Healthy Japanese Postmenopausal Women

Hirotaka NAGASHIMA, Masashi HIRAYAMA, Hiroaki OHISHI, Ichiro OIKAWA

公開日: 2017年08月19日

p.121-129

Background and objectives: Risedronate is an anti-resorptive agent commonly used for the treatment of osteoporosis. This study investigated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of risedronate to optimize the monthly dose in healthy Japanese postmenopausal women.
Methods: In this single-center, double-blinded, placebo-controlled study, subjects were randomized to receive risedronate (n＝8 per dose regimen) or placebo (n＝2 per dose regimen). Dosing regimens were either weekly dose of 17.5 mg for 4 consecutive wks, or single monthly dose (50, 75, 100, 125, or 150 mg). Safety was assessed by monitoring adverse events (AEs) and laboratory parameters. Dose proportionality was assessed using power model. PD analysis was performed using bone turnover markers (BTMs) and PK/PD analysis was performed using nonlinear mixed effect model.
Results: Out of 40 enrolled subjects, 38 completed the study. Administration of the monthly doses of 125 and 150 mg were cancelled. AEs were reported by 26/32 (81%) subjects (5 subjects in 17.5 mg group, 6 subjects in 50 mg group, 7 subjects in 75 mg group, and 8 subjects in 100 mg group) who received risedronate, however, most of AEs were mild. Dose over proportionality was implied for tested PK parameters. No obvious difference was observed between 75 and 100 mg administration for AUEC of BTMs. The final PK/PD model predicted that both uNTX/Cr and uCTX/Cr levels were similarly reduced with 75 mg monthly dose and 17.5 mg weekly dose.
Conclusion: Oral risedronate in the monthly doses of 50, 75 and 100 mg was found to be safe and well tolerated. PK and PD analyses suggested 75 mg monthly dose has comparable PD effects to 17.5 mg weekly dose.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Galcanezumab, a Monoclonal Antibody to Calcitonin Gene-Related Peptide, in Healthy Japanese and Caucasian Subjects

Masako NAKANO, Kazunori UENAKA, William KIELBASA, Yuri MATSUYAMA, Akichika OZEKI, Mosun A. AYAN-OSHODI

公開日: 2017年08月19日

p.131-139

Galcanezumab, a humanized monoclonal calcitonin gene-related peptide (CGRP) antibody, is being developed for cluster headache and migraine prevention. This study evaluated galcanezumab safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy Japanese and Caucasian subjects. Galcanezumab or placebo was administered as subcutaneous injections to 4 singledose cohorts (5, 50, 120, 300 mg) and 1 multiple-dose cohort (3 consecutive, 300-mg doses, every 4 weeks). Safety measurements included treatment-emergent adverse events (TEAEs), vital signs, electrocardiograms, clinical laboratory tests, and anti-drug antibodies (ADA). Blood samples were analyzed for serum galcanezumab and plasma CGRP concentrations.
Twenty-five Japanese and twenty Caucasians, 22 to 63 years of age, were enrolled; 27 received a single dose (N＝6 to 8 per dose level), 8 received multiple doses, and 10 received placebo (8 single dose, 2 multiple dose). Forty-one subjects completed the study (24 single dose, 7 multiple dose, 10 placebo). Galcanezumab was well tolerated in Japanese and Caucasian subjects. There were no apparent dose-related increases in TEAEs or changes in vital signs, electrocardiogram parameters, laboratory values, or treatment-emergent ADA. Following single and multiple doses, maximum galcanezumab concentrations were observed approximately 5 to 9 days postdose and mean half-life was about 3 to 4 weeks. Increases in area under the concentration-time curve and maximum observed concentration were dose proportional. Galcanezumab pharmacokinetics and pharmacodynamics were similar between Japanese and Caucasian subjects. Plasma CGRP concentrations increased following galcanezumab administration consistent with CGRP (target) binding to galcanezumab (antibody). These data support further development of galcanezumab in Japanese patients.

特別寄稿

神経変性疾患に対するリバーストランスレーショナルリサーチの基盤としての患者レジストリおよびバイオバンク

勝野雅央, 橋詰淳, 中村治雅, 小野賢二郎, 湯地晃一郎, 山田雅信, 渡邉琢也, 一丸勝彦, 加藤直人, 井上隆弘, 草間真紀子, 水島洋, 藤本陽子, 秋元周, 小林潔, 大脇健二, 上杉幸嗣

公開日: 2017年08月19日

p.141-147

本文PDF[868K]

REPORT

2015 年度日本臨床薬理学会海外研修員報告：研修完了報告書

加藤隆児

公開日: 2017年08月19日

p.149-151

本文PDF[1099K]

訂正

公開日: 2017年08月19日

p.90E

本文PDF[440K]

5件の該当記事より1～5件を表示しています。

ページトップへ

システムメンテナンス

システムメンテナンスのため、以下の時間帯にサービスを停止させていただきます。
平成29年
10月28日(土) 7:00 ～ 17:00
※作業終了次第時間内でもサービスを再開いたします。

詳細

J-STAGEからのお知らせ

2017年10月01日
1.
「利用学協会様向けの改定後の利用規約(平成29年10月1日施行)を掲載しました。（詳細はこちら）」
2.
「J-STAGE利用者満足度調査アンケートの結果を掲載いたしました。（詳細はこちら）」

2016年05月18日
新しい画面インターフェース「J-STAGE評価版」( https://jstagebeta.jst.go.jp/ )を公開しました。

2015年05月01日
J-STAGEを騙った「なりすましメール」にご注意ください

バックナンバー

巻号一覧
臨床薬理

臨床薬理 Vol. 48(2017) No. 4

原著

Optimizing a Single Monthly Dose of Risedronate Based on its Weekly Dose in Healthy Japanese Postmenopausal Women

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Galcanezumab, a Monoclonal Antibody to Calcitonin Gene-Related Peptide, in Healthy Japanese and Caucasian Subjects

特別寄稿

神経変性疾患に対するリバーストランスレーショナルリサーチの基盤としての患者レジストリおよびバイオバンク

REPORT

2015 年度日本臨床薬理学会海外研修員報告：研修完了報告書

訂正

訂正

システムメンテナンス

J-STAGEからのお知らせ

ジャーナルツール

この資料を共有

巻号一覧 臨床薬理

臨床薬理 Vol. 48(2017) No. 4

原著

Optimizing a Single Monthly Dose of Risedronate Based on its Weekly Dose in Healthy Japanese Postmenopausal Women

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Galcanezumab, a Monoclonal Antibody to Calcitonin Gene-Related Peptide, in Healthy Japanese and Caucasian Subjects

特別寄稿

神経変性疾患に対するリバーストランスレーショナルリサーチの基盤としての患者レジストリおよびバイオバンク

REPORT

2015 年度日本臨床薬理学会海外研修員報告： 研修完了報告書

訂正

訂正

システムメンテナンス

J-STAGEからのお知らせ

ジャーナルツール

この資料を共有

巻号一覧
臨床薬理

2015 年度日本臨床薬理学会海外研修員報告：研修完了報告書